Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma | Zendy

Mark Roschewski | Zendy; Kieron Dunleavy | Zendy; Jeremy S. Abramson | Zendy; Bayard L. Powell | Zendy; Brian K. Link | Zendy; Prapti A. Patel | Zendy; Philip J. Bierman | Zendy; Deepa Jagadeesh | Zendy; Ronald T. Mitsuyasu | Zendy; David Peace | Zendy; Peter R. Watson | Zendy; Wahid T. Hanna | Zendy; Christopher Melani | Zendy; Andrea N. Lucas | Zendy; Seth M. Steinberg | Zendy; Stefania Pittaluga | Zendy; Elaine S. Jaffe | Zendy; Jonathan W. Friedberg | Zendy; Brad S. Kahl | Zendy; Richard F. Little | Zendy; Nancy L. Bartlett | Zendy; Michelle A. Fanale | Zendy; Ariela Noy | Zendy; Wyndham H. Wilson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Author(s) -

Mark Roschewski,

Kieron Dunleavy,

Jeremy S. Abramson,

Bayard L. Powell,

Brian K. Link,

Prapti A. Patel,

Philip J. Bierman,

Deepa Jagadeesh,

Ronald T. Mitsuyasu,

David Peace,

Peter R. Watson,

Wahid T. Hanna,

Christopher Melani,

Andrea N. Lucas,

Seth M. Steinberg,

Stefania Pittaluga,

Elaine S. Jaffe,

Jonathan W. Friedberg,

Brad S. Kahl,

Richard F. Little,

Nancy L. Bartlett,

Michelle A. Fanale,

Ariela Noy,

Wyndham H. Wilson

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.00303

Subject(s) - medicine , vincristine , international prognostic index , etoposide , clinical endpoint , chemotherapy , febrile neutropenia , epoch (astronomy) , lymphoma , neutropenia , mucositis , surgery , cyclophosphamide , oncology , gastroenterology , randomized controlled trial , stars , physics , astronomy

Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research